These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 8163669

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.
    Shachter NS, Ebara T, Ramakrishnan R, Steiner G, Breslow JL, Ginsberg HN, Smith JD.
    J Clin Invest; 1996 Aug 01; 98(3):846-55. PubMed ID: 8698877
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T, Ramakrishnan R, Steiner G, Shachter NS.
    J Clin Invest; 1997 Jun 01; 99(11):2672-81. PubMed ID: 9169497
    [Abstract] [Full Text] [Related]

  • 7. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia.
    Huang Y, Liu XQ, Rall SC, Taylor JM, von Eckardstein A, Assmann G, Mahley RW.
    J Biol Chem; 1998 Oct 09; 273(41):26388-93. PubMed ID: 9756870
    [Abstract] [Full Text] [Related]

  • 8. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC, Dahlmans VE, van Gorp PJ, van Dijk KW, Breuer ML, Hofker MH, Havekes LM.
    J Clin Invest; 1996 Nov 15; 98(10):2259-67. PubMed ID: 8941642
    [Abstract] [Full Text] [Related]

  • 9. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall A.
    J Clin Invest; 1994 Dec 15; 94(6):2457-67. PubMed ID: 7989603
    [Abstract] [Full Text] [Related]

  • 10. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice.
    Allan CM, Taylor JM.
    J Lipid Res; 1996 Jul 15; 37(7):1510-8. PubMed ID: 8827523
    [Abstract] [Full Text] [Related]

  • 11. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.
    Berbée JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC.
    J Lipid Res; 2005 Feb 15; 46(2):297-306. PubMed ID: 15576844
    [Abstract] [Full Text] [Related]

  • 12. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1.
    Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ.
    Kidney Int; 2000 Sep 15; 58(3):1238-46. PubMed ID: 10972686
    [Abstract] [Full Text] [Related]

  • 13. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD, Novoselov AV, Visvikis S, Siest G, Yakushkin VV, Tsibulsky V.
    Biol Chem; 2005 May 15; 386(5):441-52. PubMed ID: 15927888
    [Abstract] [Full Text] [Related]

  • 14. Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice.
    van der Hoogt CC, Berbée JF, Espirito Santo SM, Gerritsen G, Krom YD, van der Zee A, Havekes LM, van Dijk KW, Rensen PC.
    Biochim Biophys Acta; 2006 Feb 15; 1761(2):213-20. PubMed ID: 16478678
    [Abstract] [Full Text] [Related]

  • 15. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL.
    Westerterp M, de Haan W, Berbée JF, Havekes LM, Rensen PC.
    J Lipid Res; 2006 Jun 15; 47(6):1203-11. PubMed ID: 16537968
    [Abstract] [Full Text] [Related]

  • 16. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J, Escolà-Gil JC, Rotllan N, Fiévet C, Vallez E, de la Torre C, Ribas V, Sloan JH, Blanco-Vaca F.
    Arterioscler Thromb Vasc Biol; 2010 Feb 15; 30(2):232-8. PubMed ID: 19910634
    [Abstract] [Full Text] [Related]

  • 17. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject.
    Huff MW, Evans AJ, Wolfe BM, Connelly PW, Maguire GF, Strong WL.
    J Lipid Res; 1990 Mar 15; 31(3):385-96. PubMed ID: 2341805
    [Abstract] [Full Text] [Related]

  • 18. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
    Jong MC, Havekes LM.
    Int J Tissue React; 2000 Mar 15; 22(2-3):59-66. PubMed ID: 10937355
    [Abstract] [Full Text] [Related]

  • 19. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase.
    Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS.
    J Lipid Res; 2002 Dec 15; 43(12):2136-45. PubMed ID: 12454276
    [Abstract] [Full Text] [Related]

  • 20. Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII.
    Wei J, Ouyang H, Wang Y, Pang D, Cong NX, Wang T, Leng B, Li D, Li X, Wu R, Ding Y, Gao F, Deng Y, Liu B, Li Z, Lai L, Feng H, Liu G, Deng X.
    FEBS J; 2012 Jan 15; 279(1):91-9. PubMed ID: 22023023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.